Exploring the role of immune checkpoints IDO1 and PDL1 in Cutaneous Leishmaniasis (CL)
Explore how immune checkpoints IDO1 and PDL1 influence the immune response in Cutaneous Leishmaniasis (CL).
Explore how immune checkpoints IDO1 and PDL1 influence the immune response in Cutaneous Leishmaniasis (CL).
Lyme disease, a disease transmitted when deer ticks feed on infected animals like deer and rodents, and then bite humans, impacts nearly half a million individuals in the U.S. annually.
Mosaic Therapeutics, Ltd ('Mosaic') a targeted oncology therapeutics company dedicated to resolving cancer's complexity with new combination therapies for patients, today announces the in-licensing of two clinical-stage oncology programs from…
CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D…
Built on the legacy of three trusted brands - BioTrading, Redipor by Cherwell, and NEL - Redipor by AnalytiChem brings together over 150 years of prepared media expertise, innovation and…
The Biothreats Emergence, Analysis and Communications Network (BEACON) leverages advanced artificial intelligence (AI), large language models (LLMs) and a network of globally based experts to rapidly collect, analyze, and disseminate…
Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions.
A new strategy for tuberculosis (TB) screening, proposed by a team of researchers led by Queen Mary University of London, provides a solution to problems with current TB screening, which…
For many cancer patients, side effects from radiation can be debilitating. But a new way of delivering radiation treatment has proven effective at eliminating a hard-to-treat cancer with the only…
Researchers have identified a key enzyme driving forms of Parkinson’s, and have shown how blocking it restores normal function in animal and cell models – offering a promising new drug…